These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38980202)

  • 1. Treatment response amplitude and timing in chronic inflammatory demyelinating polyneuropathy with routine care: Study of a UK cohort.
    Rajabally YA; Min YG; Nazeer KK; Englezou C
    Eur J Neurol; 2024 Oct; 31(10):e16399. PubMed ID: 38980202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment timing and choice of outcome measure in determining treatment response in chronic inflammatory demyelinating polyneuropathy: A post hoc analysis of the PRISM trial.
    Rajabally YA; Ouaja R; Kasiborski F; Pujol S; Nobile-Orazio E
    Muscle Nerve; 2022 Nov; 66(5):562-567. PubMed ID: 36057106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic inflammatory demyelinating polyneuropathy associated with diabetes: a European multicentre comparative reappraisal.
    Rajabally YA; Peric S; Cobeljic M; Afzal S; Bozovic I; Palibrk A; Basta I
    J Neurol Neurosurg Psychiatry; 2020 Oct; 91(10):1100-1104. PubMed ID: 32868389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study.
    Dunnigan SK; Ebadi H; Breiner A; Katzberg HD; Barnett C; Perkins BA; Bril V
    PLoS One; 2014; 9(2):e89344. PubMed ID: 24586703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression.
    Hung SKY; Hiew FL; Viswanathan S; Puvanarajah S
    J Peripher Nerv Syst; 2018 Sep; 23(3):183-189. PubMed ID: 30027593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis.
    Guptill JT; Runken MC; Eaddy M; Lunacsek O; Fuldeore RM
    Am Health Drug Benefits; 2019 May; 12(3):127-135. PubMed ID: 31346365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
    Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
    J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness.
    Mygland A; Monstad P
    Arch Neurol; 2003 Feb; 60(2):260-4. PubMed ID: 12580713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy.
    Grüter T; Motte J; Fisse AL; Bulut Y; Köse N; Athanasopoulos D; Otto S; Yoon MS; Schneider-Gold C; Gold R; Pitarokoili K
    Eur J Neurol; 2020 Dec; 27(12):2595-2603. PubMed ID: 32794258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients.
    Alessandro L; Pastor Rueda JM; Wilken M; Querol L; Marrodán M; Acosta JN; Rivero A; Barroso F; Farez MF
    J Peripher Nerv Syst; 2018 Sep; 23(3):154-158. PubMed ID: 29603827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal Dispersion and Duration of the Distal Compound Muscle Action Potential Do Not Distinguish Diabetic Sensorimotor Polyneuropathy From Chronic Inflammatory Demyelinating Polyneuropathy.
    Alcantara M; Ngo M; de la Cruz J; Menon D; Barnett-Tapia C; Katzberg H; Bril V
    Front Neurol; 2022; 13():872762. PubMed ID: 35557614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: A European collaborative study.
    Rajabally YA; Peric S; Bozovic I; Loo LK; Kalac A; Palibrk A; Basta I
    Muscle Nerve; 2021 Dec; 64(6):657-661. PubMed ID: 34263956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy.
    Chaudhary UJ; Rajabally YA
    J Neurol; 2021 Apr; 268(4):1366-1373. PubMed ID: 33170339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Afzal S; Ghasemi M
    Muscle Nerve; 2021 Jul; 64(1):37-42. PubMed ID: 33835480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different types of chronic inflammatory demyelinating polyneuropathy have a different clinical course and response to treatment.
    Jann S; Beretta S; Bramerio MA
    Muscle Nerve; 2005 Sep; 32(3):351-6. PubMed ID: 16003765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years.
    Hiew FL; Ong JJ; Viswanathan S; Puvanarajah S
    J Clin Neurosci; 2018 Apr; 50():203-207. PubMed ID: 29398193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute-onset chronic inflammatory demyelinating polyneuropathy: An electrodiagnostic study.
    Anadani M; Katirji B
    Muscle Nerve; 2015 Nov; 52(5):900-5. PubMed ID: 25809534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients.
    Dorst J; Ludolph AC; Senel M; Tumani H
    J Neurol; 2018 Dec; 265(12):2906-2915. PubMed ID: 30293110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome.
    Vina ER; Fang AJ; Wallace DJ; Weisman MH
    Semin Arthritis Rheum; 2005 Dec; 35(3):175-84. PubMed ID: 16325658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post-hoc analysis of the immunoglobulin overtreatment in CIDP trial.
    van Veen R; Wieske L; Lucke I; Adrichem ME; Merkies ISJ; van Schaik IN; Eftimov F
    J Peripher Nerv Syst; 2022 Jun; 27(2):144-158. PubMed ID: 35507446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.